Epinephrine is used to treat severe allergic reactions (anaphylaxis) and can quickly reverse life-threatening symptoms like difficulty breathing and dangerous drops in blood pressure. It's also used to treat severe asthma attacks and to restart the heart during cardiac emergencies.[2] Adrenaline is currently approved and in use across 75 indications[4].[1]
Adrenaline is one of 1202 small molecule programs targeting Benign Muscle Neoplasm. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1639 competitors in Non-Small Cell Lung Cancer
Adrenaline
Gemzar
Lenvima
Vizimpro
Immunotherapy
Remeron
Tyrosine Kinase Inhibitor
Vibramycin
Treatment
Vidaza
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
BRONKAID MIST
NDA NDA016803
Jan 1, 1982
PRIMATENE MIST
NDA NDA016126
Aug 3, 1995
EPI E Z PEN JR
NDA NDA019430
Feb 5, 1999
SUS-PHRINE SULFITE FREE
NDA NDA007942
Nov 25, 2009
ADRENACLICK
NDA NDA020800
Dec 7, 2012
ADRENALIN
NDA NDA204200
Dec 18, 2013
ADRENALIN
NDA NDA204640
Nov 17, 2017
AUVI-Q
NDA NDA201739
Sep 27, 2018
SYMJEPI
NDA NDA207534
Nov 7, 2018
PRIMATENE MIST
NDA NDA205920
Nov 5, 2019
EPINEPHRINE
NDA NDA209359
Aug 15, 2022
EPINEPHRINE
NDA NDA211363
Apr 21, 2023
ADRENALIN
NDA NDA215875
Mar 4, 2024
EPINEPHRINE
NDA NDA205029
Mar 5, 2025
NEFFY
NDA NDA214697
Mar 13, 2025
EPINEPHRINE
NDA NDA215425
Mar 30, 2026
EPINEPHRINE
NDA NDA220626
Sources
Details
Patent Cliff
Dec 12, 2026
Earliest patent expiration — generic entry possible after this date